Ann Dermatol.  2015 Apr;27(2):178-183. 10.5021/ad.2015.27.2.178.

Evaluation of Advanced Oxidation Protein Products, Prooxidant-Antioxidant Balance, and Total Antioxidant Capacity in Untreated Vitiligo Patients

• Guntas G
• Engin B
• Ekmekci OB
• Kutlubay Z
• Ekmekci H
• Songur A
• Uzuncakmak TKU
• Vehid HE
• Serdaroglu S
• Tuzun Y
• Uzun H

• KMID: 2264807
• DOI: http://doi.org/10.5021/ad.2015.27.2.178

Abstract

BACKGROUND
Vitiligo is a chronic, common disease of unknown etiology, and oxidative stress is suggested to have a role in its etiopathogenesis.
OBJECTIVE
Advanced oxidation protein products (AOPPs), prooxidant-antioxidant balance (PAB), and ferric-reducing antioxidant power (FRAP) were evaluated regarding their role in the pathogenesis of vitiligo as well as their relationship with clinical presentation and disease severity, and these parameters were compared with those of healthy controls.
METHODS
The study included 53 patients with vitiligo and 20 healthy volunteers as the control group. AOPP level, PAB, and FRAP were determined by colorimetric methods.
RESULTS
PAB and FRAP level were significantly higher in patients with vitiligo than in healthy controls (p<0.001). The AOPP levels in vitiligo patients were not statistically significantly higher than those in healthy controls. The Vitiligo Area Scoring Index positively correlated with disease duration (r(s): 0.531, p<0.001).
CONCLUSION
To the best of our knowledge, this is the first report of AOPP and PAB status in vitiligo. PAB may be used as an indicator for oxidative stress in the etiopathogenesis of vitiligo. Our results show that these parameters may play a major role in the melanocyte damage observed in vitiligo. Further studies are required to confirm the mechanisms underlying this effect.

Keyword

Advanced oxidation protein products; Ferric-reducing antioxidant power; Prooxidant-antioxidant balance; Vitiligo

MeSH Terms

Advanced Oxidation Protein Products*
Healthy Volunteers
Humans
Melanocytes
Oxidative Stress
Vitiligo*
Advanced Oxidation Protein Products

Figure

• 

  Fig. 1 Relationship between the Vitiligo Area Scoring Index (VASI) and disease duration in patients with vitiligo.

Reference

1. Denli Y, Acar MA, Sönmezoğlu Maraklı S, Yücel A. Vitiligo. Disorders of pigmentation. In : Tüzün Y, Gürer MA, Serdaroğlu S, Oğuz O, Aksungur V, editors. Dermatology. 3rd ed. İstanbul: Nobel Publishing;2008. p. 1465–1490.

2. Kutlubay Z, Uzuncakmak TK, Engin B, Tüzün Y. Vitiligo and oxidative stress. J Turk Acad Dermatol. 2011; 5:1154r1.

3. Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elassiuty YE, Kemp EH, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008; 17:139–140. discussion 141-160.

4. Karaca Ş, Güder H. Antioxidant system in dermatology. Turk J Dermatol. 2009; 3:32–39.

5. Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids. 2011; 46:333–340.

6. Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, Ramachandran AV, et al. Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol. 2013; 22:245–250.

7. Alamdari DH, Ghayour-Mobarhan M, Tavallaie S, Parizadeh MR, Moohebati M, Ghafoori F, et al. Prooxidant-antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease. Clin Biochem. 2008; 41:375–380.

8. Arican O, Kurutas EB. Oxidative stress in the blood of patients with active localized vitiligo. Acta Dermatovenerol Alp Pannonica Adriat. 2008; 17:12–16.

9. Jain A, Mal J, Mehndiratta V, Chander R, Patra SK. Study of oxidative stress in vitiligo. Indian J Clin Biochem. 2011; 26:78–81.

10. Koca R, Armutcu F, Altinyazar HC, Gürel A. Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo. Clin Exp Dermatol. 2004; 29:406–409.

11. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996; 239:70–76.

12. Karacay O, Sepici-Dincel A, Karcaaltincaba D, Sahin D, Yalvaç S, Akyol M, et al. A quantitative evaluation of total antioxidant status and oxidative stress markers in preeclampsia and gestational diabetic patients in 24-36 weeks of gestation. Diabetes Res Clin Pract. 2010; 89:231–238.

13. Breusing N, Grune T. Biomarkers of protein oxidation from a chemical, biological and medical point of view. Exp Gerontol. 2010; 45:733–737.

14. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta. 2003; 329:23–38.

15. Zhou Q, Wu S, Jiang J, Tian J, Chen J, Yu X, et al. Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients. Nephrology (Carlton). 2012; 17:642–649.

16. Cakatay U, Kayali R, Uzun H. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clin Exp Med. 2008; 8:51–57.

17. Gelisgen R, Genc H, Kayali R, Oncul M, Benian A, Guralp O, et al. Protein oxidation markers in women with and without gestational diabetes mellitus: a possible relation with paraoxonase activity. Diabetes Res Clin Pract. 2011; 94:404–409.

18. Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci (Lond). 2011; 120:99–120.

19. Ozyazgan S, Andican G, Erman H, Tuzcu A, Uzun H, Onal B, et al. Relation of protein oxidation parameters and disease activity in patients with Behçet's disease. Clin Lab. 2013; 59:819–825.

20. Schallreuter KU. Successful treatment of oxidative stress in vitiligo. Skin Pharmacol Appl Skin Physiol. 1999; 12:132–138.

21. Akoglu G, Emre S, Metin A, Akbas A, Yorulmaz A, Isikoglu S, et al. Evaluation of total oxidant and antioxidant status in localized and generalized vitiligo. Clin Exp Dermatol. 2013; 38:701–706.

22. Boisseau-Garsaud AM, Garsaud P, Lejoly-Boisseau H, Robert M, Quist D, Arveiler B. Increase in total blood antioxidant status and selenium levels in black patients with active vitiligo. Int J Dermatol. 2002; 41:640–642.